For direct compression tablets, the hydrochloride salt of (2R,3S/2S,3R)-3-(4-chloro-5-fluoro-6-pyrimidinyl)-2-(2,4-difluorophenyl)butan-2-ol is blended as a dry powder with microcrystalline cellulose, anhydrous lactose or mannitol, and crospovidone at 2–5% w/w. The API particle size D₁₀ should remain above 20 μm, D₅₀ between 75–150 μm, and D₉₀ below 300 μm to prevent blend segregation; bulk density in the range 0.38–0.52 g/mL and tapped density 0.48–0.65 g/mL yield a Carr index below 25, which is acceptable for high-speed rotary presses with D-tooling. Before compression, the mixture is passed through a 600 μm sieve and lubricated with 0.25–1.0% w/w magnesium stearate for 3–5 minutes at 20–30 rpm in a V-blender; over-lubrication above 1.0% w/w reduces tablet hardness and shifts dissolution to slower curves due to hydrophobic film formation on the API surfaces. The compression step is run on a 45-station rotary press with pre-compression force 2–5 kN and main compression force 8–18 kN, yielding tablets of hardness 8–14 kP, friability below 0.8% in a USP <1216> friabilator, and thickness variation within ±5% of target. Tablet cores contain 5–30% w/w API, with the upper limit constrained by tableting properties of the raw drug substance; if the API is milled to D₉₀ below 150 μm, higher drug loads up to 60% w/w are feasible but flow and ejection forces must be revalidated. In-process controls include chiral HPLC with a limit of quantitation below 0.05% w/w for the undesired stereoisomer, blend uniformity testing with 10 sampling points and RSD below 5.0%, and weight uniformity using USP <905> with acceptance value below 15.0. Dissolution testing for an immediate-release tablet is performed in USP <711> Apparatus 2 at 75 rpm and 37 °C using 900 mL of 0.1 M hydrochloric acid with 0.2% sodium lauryl sulfate; a typical release criterion is Q ≥ 80% at 30 minutes, but product-specific justification is required if the formulation contains pH modifiers or enteric coatings.

What Limits Wet Granulation Solvent Selection for This Chloropyrimidine Hydrochloride?

Aqueous granulation of this API is performed only when the chloropyrimidine ring is protected from hydrolysis by maintaining the granulating fluid pH below 5.0 and by limiting free water content to ≤5% v/v through the use of anhydrous ethanol or isopropanol. A high-shear granulator of 65 L working volume is charged with the API, mannitol or anhydrous lactose, and croscarmellose sodium at 2–5% w/w; povidone K30 is predissolved at 3–5% w/w in the alcoholic binder solution and introduced at an impeller speed of 150–250 rpm with chopper speed 1500–2500 rpm over 2–4 minutes. The wet mass endpoint is controlled by power consumption, with a conservative endpoint range of 6–12 N·m at the granulator shaft; this range must be re-established for the specific production train because published data for this particular formulation configuration is limited. After wet milling through a 1.5 mm screen, the granules are transferred to a fluid-bed dryer with inlet air 50–65 °C and product temperature maintained at ≤40 °C until moisture by loss on drying is ≤2.0% w/w or Karl Fischer testing according to USP <921> gives ≤2.0% water. Dry granules are milled through a 0.8–1.0 mm screen and lubricated with sodium stearyl fumarate at 0.5–1.5% w/w rather than magnesium stearate to reduce the risk of dissolution slowdown. Terminal tablets or capsules produced from this granulation are tested for chiral purity, related substances, content uniformity under USP <905>, and dissolution under USP <711>; free-base precipitation is controlled by excluding amine-based granulating aids and by using citric acid rather than ammonia or meglumine for pH adjustment.

When low-dose oral capsules are filled on an automatic capsule machine, the milled API is pre-blended with anhydrous lactose monohydrate and pregelatinized starch so that the D₅₀ ratio between API and diluent remains below approximately 1.5:1, reducing segregation during transfer through a forced-feed auger. The blend is lubricated with 0.5% w/w magnesium stearate for 3 minutes at 20 rpm, and colloidal silicon dioxide at 0.2–0.5% w/w is added as a glidant to improve mass flow into size 2–3 gelatin or hydroxypropyl methylcellulose capsule shells. On a Bosch GKF series or equivalent production capsule filler, fill weight is maintained at 100–200 mg per capsule with 10-point blend uniformity RSD below 5.0%; weight variation is controlled under USP <905> with acceptance value below 15.0. Hydroxypropyl methylcellulose shells with shell moisture of 3–7% are preferred over gelatin shells with shell moisture of 13–16% when the API salt is hygroscopic or when storage at 40 °C/75% RH is required. The terminal capsule assay is controlled at 90–110% of label claim, and dissolution in USP <711> is usually conducted with 900 mL of 0.1 M hydrochloric acid at 75 rpm and 37 °C; product-specific dissolution acceptance is required if the formulation contains pH modifiers, but immediate-release capsules generally require Q ≥ 80% at 30 minutes.

If Roller Compaction Replaces Aqueous Granulation, Ribbon Relative Density Above 0.82 Shifts Dissolution

Dry granulation via roller compaction is used when the API is exposed to moisture or elevated temperature during wet processing and where hydrolytic degradation of the chloropyrimidine group must be avoided. A roller compactor with ribbed rolls is operated at hydraulic pressure 4–10 kN/cm of roll width, roll gap 1.5–2.5 mm, and roll speed 3–8 rpm; ribbon relative density is calculated from ribbon mass, volume, and true density, and the target range is 0.75–0.85. When ribbon relative density exceeds 0.82, ribbon porosity is insufficient and tablet dissolution shifts to slower release because the compacted API-rich granules retain cohesive bridges after tableting; conversely, ribbon relative density below 0.70 generates excessive fines and poor granule strength. After compaction, ribbons are milled through a 0.8–1.25 mm screen, and the fraction below 150 μm should not exceed 35% w/w to avoid capping during compression and segregation during capsule filling. The milled granules are blended with croscarmellose sodium 2–5% w/w as an extragranular disintegrant and with sodium stearyl fumarate 0.5% w/w as lubricant. Tablet hardness, friability, and dissolution are controlled under USP <1216>, USP <701>, and USP <711>; an immediate-release tablet produced from roller-compacted granules normally disintegrates within 15 minutes in 0.1 M hydrochloric acid at 37 °C, but product-specific acceptance must be confirmed because the raw API particle properties and polymorphic form affect ribbon densification.

Controlling Residual Moisture in Lyophilized Vials after Isobaric Desorption

The sterile injectable configuration for this API is a lyophilized cake in Type I borosilicate glass vials, produced under aseptic processing according to EU GMP Annex 1, ISO 14644-1:2015, and 21 CFR Part 211. The pre-lyophilization solution contains the hydrochloride salt in a citrate buffer of 10–50 mM at pH 3.0–4.5, with mannitol at 4–6% w/v as a crystalline bulking agent; sucrose at 2–5% w/v is substituted when an amorphous cake matrix is required for faster reconstitution. The solution is filtered through a 0.45 μm prefilter and a 0.22 μm polyvinylidene difluoride membrane before filling at 5 mL nominal volume into 10 mL vials. Freezing is performed at shelf temperature -45 °C for 2 hours; primary drying is operated at shelf temperature -25 °C and chamber pressure 100–150 mTorr until the product temperature approaches the collapse temperature measured by freeze-drying microscopy. The collapse temperature for this specific formulation must be determined experimentally; published data for this exact configuration is limited, so a conservative primary drying cycle holds the product temperature at least 2–3 °C below the measured onset of collapse. Secondary drying is performed at shelf temperature 25 °C and chamber pressure 50 mTorr for 6–10 hours; residual moisture by Karl Fischer coulometry is maintained at ≤1.0% w/w, and headspace oxygen after nitrogen purging is held at ≤1.0%. Vial container closure integrity is verified by vacuum decay using USP <1207>, and the lyophilized product is tested for sterility, bacterial endotoxins, particulate matter, and residual moisture.

For ready-to-infuse intravenous admixtures, the sterile API solution is first reconstituted or diluted under aseptic conditions into 0.9% sodium chloride injection or 5% dextrose injection, adjusted to pH 3.0–5.5 with citric acid or hydrochloric acid, and filled into polyolefin or DEHP-free PVC infusion bags at concentrations of 0.5–5.0 mg/mL. Terminal heat sterilization is not applied because the chloropyrimidine ring is susceptible to hydrolytic degradation at elevated temperature; processing is therefore restrictively aseptic with sterile filtration through a 0.22 μm membrane. The pH range is selected to keep the hydrochloride salt dissolved while avoiding free-base precipitation; above pH 6.0, precipitate formation may occur and the chloropyrimidine may undergo base-catalyzed hydrolysis. In-line filtration during administration through a 0.2 μm low-binding polyethersulfone filter is used to remove inadvertent particulate matter, but nylon filters should be avoided until product-specific adsorption data are available. The admixture is protected from light because the fluoropyrimidine chromophore can undergo photodegradation; in-use hold times are limited to 24 hours at 2–8 °C or 8 hours at 20–25 °C unless product-specific compatibility testing supports longer intervals. Infusion bag materials, port tubing, and elastomeric closures must be screened for extractables and leachables under ICH Q3C residual-solvent expectations and ICH Q3D elemental-impurity limits; published data for this specific formulation configuration is limited, so compatibility matrices must be generated during late-phase development.

Oral Granule Filling with 0.5% Colloidal Silicon Dioxide and 35% Mannitol in Alu-Alu Sachets

Single-dose oral granules containing the hydrochloride salt are produced from roller-compacted or non-aqueous granulated material for reconstitution in water immediately before oral administration. The dry granule formulation contains 10–50% w/w API, mannitol at 30–40% w/w, microcrystalline cellulose at 5–10% w/w, sodium citrate at 1–2% w/w, sucralose at 0.1–0.3% w/w, and xanthan gum at 1–2% w/w; colloidal silicon dioxide at 0.5% w/w is added before sachet filling to control interparticulate adhesion and guard against caking at 25 °C/60% RH. The granule D₅₀ is controlled at 200–500 μm with fines below 75 μm limited to ≤15% w/w; this particle-size distribution provides acceptable flow on a vertical form-fill-seal sachet machine and avoids segregation of API-rich fines during hopper vibration. Sachets are fabricated from cold-form aluminum-aluminum laminate with a moisture vapor transmission rate below 0.005 g/m²/24 h and oxygen transmission below 0.01 cm³/m²/24 h/0.1 MPa; the barrier maintains granule moisture at ≤2.0% w/w through the labeled shelf life and prevents hydrolytic degradation of the chloropyrimidine ring. The reconstituted suspension is prepared by emptying one sachet into 10 mL of water at 20–25 °C, stirring for 30–60 seconds, and administering immediately; sedimentation volume and redispersibility are controlled according to Ph. Eur. 2.9.36 with product-specific limits. Content uniformity is tested under USP <905>, and dissolution of the suspended granules is evaluated in USP <711> Apparatus 2 with 900 mL of 0.1 M hydrochloric acid at 75 rpm and 37 °C; immediate release is typically defined as Q ≥ 80% at 30 minutes, but the exact specification is derived from the regulatory filing for the finished oral granule product.